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Abstract
Objective: To evaluate levels of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in
second trimester amniotic fluid of women with hypertensive disorders compared to normotensive
women.
Study Design: Amniotic fluid was obtained from 133 women undergoing genetic second
trimester amniocentesis. Zymography was performed for MMP characterization and an MMP-2
ELISA kit was used to determine MMP-2 levels. TIMP-2 expression was evaluated using western
blot.
Results: Mean amniotic fluid MMP-2 and TIMP-2 levels were significantly higher in women who
developed a hypertensive disorder compared to normotensive women (P < 0.0004 and P < 0.01,
respectively). When subdivided into subgroups, amniotic fluid from women who eventually
developed preeclampsia or superimposed preeclampsia showed significantly higher MMP-2 levels
than normotensive women (P < 0.05). However, no statistical difference in MMP-2 levels was found
between patients with gestational hypertension and normotensive patients.
Conclusion: Higher amniotic fluid MMP-2 and TIMP-2 levels are found in women who eventually
develop preeclampsia.
Background
Preeclampsia is a multi-system disorder of pregnancy
characterized by hypertension, proteinuria and general-
ized systemic vasoconstriction. The disorder is diagnosed
in the latter half of pregnancy, effects about 5% of preg-
nancies and accounts for considerable mortality and mor-
bidity [1].
Several models have been proposed for the pathogenesis
of preeclampsia. [2-4]. Prevailing evidence suggest insuffi-
cient trophoblast invasion of the maternal spiral arteries
as the main pathogenesis of the disease. Whereas in nor-
mal pregnancy the luminal diameter of the spiral arteries
is greatly increased and the vascular smooth muscle is
replaced by trophoblast cells, in preeclamptic pregnancies
this process is deficient. The resulting under-perfused pla-
centa attempts to compensate by promoting the secretion
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of factors into the maternal circulation causing systemic
alterations in endothelial cell function, accounting for the
clinical syndrome of preeclampsia. Although this hypoth-
esis is widely accepted, the molecular mechanisms that
regulate this pathological process are still controversial.
The role of matrix metalloproteinases (MMPs) in the
pathogenesis of preeclampsia has been given much atten-
tion in recent years [5-9]. These extra-cellular matrix-
remodeling enzymes, balanced by their tissue inhibitors
(TIMP), are essential effectors of developmental processes
including cell migration, cell proliferation, apoptosis and
tissue morphogenesis [10]. MMPs play an important role
in endothelial cell invasion, angiogenesis and in tumor
progression [11-14].
A reduction in the content and activity of MMPs in the
umbilical cord artery was found in preeclamptic pregnan-
cies compared with normotensive pregnancies [7]. Higher
levels of MMP-2 have been demonstrated in plasma of
women with preeclampsia [8]. More recent studies have
shown altered serum MMP-2 levels prior to the onset of
preeclampsia. [15].
In an effort to study the MMP profile before the onset of
clinical preeclampsia, and in a more reliably fetal-placen-
tal environment, we designed our study to measure MMP
in second trimester amniotic fluid of women with normo-




Following approval by the local ethics committee, and
informed consent from each patient, 290 samples of
amniotic fluid were collected from singleton pregnancies
during second trimester genetic amniocentesis between
June 2005 and January 2006. Ha'emek Medical Center is
the largest medical center in the area and provides genetic
amniocentesis for most women living in this part of Israel.
However, several smaller hospitals in the area provide
obstetric services. For this reason, approximately half of
the women who underwent amniocentesis in our facility
delivered elsewhere. Consequently, pregnancy follow up
was possible in 150 women who chose to deliver at
Ha'emek Medical Center. In these cases, data collected
included gestational age at delivery, method of delivery,
obstetrical complications, fetal gender, weight, apgar
score and pH value, when performed. Five of these 150
women were omitted from the study (four elective termi-
nations of pregnancy due to karyotype abnormalities and
one late missed abortion). Twelve cases in which sponta-
neous preterm delivery occurred were excluded from the
study as well.
Preeclampsia (PET) was defined as hypertension with a
systolic blood pressure >140 mmHg and/or a diastolic
blood pressure >90 mmHg in association with proteinuria
[24 h urinary protein exceeding 300 mg per 24 h or per-
sistent 30 mg/dl (1+dipstick) in random urine samples]
with or without edema. Gestational Hypertension (GH)
was defined by hypertension with systolic blood pressure
>140 mmHg and/or diastolic blood pressure >90 mmHg,
appearing for the first time after midpregnancy, without
proteinuria. Superimposed preeclampsia (sPET) was
defined as women with chronic hypertension (hyperten-
sion prior to pregnancy or early in pregnancy, i.e. <20
weeks' gestation) and new onset proteinuria.
Sample preparation
Amniotic fluid was collected from 290 women who
underwent genetic second trimester amniocentesis. One
milliliter of amniotic fluid was removed and centrifuged
at 2600 rmp for 10 minutes before storing at -80°C.
Substrate-gel-electrophoresis (zymography)
Amniotic fluid, molecular mass markers (10 ml), and
standard commercial gelatinases A and B (7 ml; Oncogene
Science, Cambridge, MA, USA) were diluted with sample
buffer (5% SDS, 20% glycerol in 0.4 mol/l Tris, pH 6.8).
Samples were electrophoresed through a 10% polyacryla-
mide gel containing 1 mg/ml gelatin. After electrophore-
sis, gelatin gels were washed twice in 2.5% Triton X-100.
Gelatin gels were incubated for 24 h at 37°C in 0.2 mol/l
NaCl, 5 mmol/l CaCl2, 0.02% Brij 35 and 50 mmol/l Tris,
pH 7.5). The buffer was decanted and the gel stained with
Coomassie Blue for 10 min at room temperature. Areas
where proteolytic activity degraded the gelatin are seen as
absence of staining. Identification of each gelatinase band
was in accordance with its molecular weight and commer-
cial standards (data not shown). These were quantified
using the BioImmaging gel Documentation system
(Dinco & Renium, Jerusalem, Israel) endowed with TINA
software (Raytest, Staubenhardt, Germany).
Western blot analysis
Amniotic fluid and molecular mass marker (10 ml) were
diluted with sample buffer (5% SDS, 20% glycerol in 0.4
mol/l Tris, pH 6.8) and subjected to 10% polyacrylamide
gel electrophoresis. After electrophoresis, the gel was
transferred onto 0.45 mm nitrocellulose membranes
(Scheicher & Schuel, Dassel, Germany). Nonspecific bind-
ing sites were blocked by incubating the nitrocellulose
membranes overnight with 20% non-fat milk. The mem-
branes were then washed twice with Tris-buffered saline,
containing 0.5% Tween-20, and incubated with mouse
antihuman TIMP-1 antibody (1.0 mg/ml; Oncogene Sci-
ence, Cambridge, MA, USA). The membranes were
washed with Tris-buffered saline, containing 0.5% Tween-
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anti-mouse rabbit secondary antibody (Jackson Immu-
noResearch, West Grove PA, USA), then detected by
enhanced chemiluminescence's (ECL; Amersham Interna-
tional) and quantified by densitometry as above.
MMP-2 Elisa-kit
Total MMP-2 (pro and active forms) levels were measured
using EIA commercial kits (cat. RPN2617, Danyelbi-
othech, Rehovot, Israel), according to the manufacturer's
recommendations. Optical density was measured at 450
nm.
Statistical analysis
Data are presented as mean ± SEM. Statistical analysis of
data was performed using Student's t-test for parametric
or Chi square test for non-parametric continuous data
when comparing two groups. SPSS statistical software was
used. A level of P < 0.05 was considered to be significant.
Results
Indications for amniocentesis were: maternal age 54%,
pathological triple test 27%, abnormal sonographic find-
ings 16% and other indications (prior history or family
history of chromosomal abnormality and patient request)
3%. A hypertensive disorder was diagnosed in 17 out of
133 pregnancies (12.8%). Five women developed GH
(3.7%), five developed PET (3.7%) and 7 developed sPET
(5.3%). In this study group all women diagnosed with
chronic hypertension eventually developed superimposed
PET. Clinical characteristics and pregnancy outcome of
the study groups are summarized in Table 1. In all cases,
both in the hypertensive and the normotensive groups, no
major fetal malformations were reported and normal
karyotype had been documented. No significant differ-
ence in maternal age, gestational age at amniocentesis,
method of delivery, cord pH or apgar scores was docu-
mented between the two groups. The hypertensive group
presented significantly lower gestational age at delivery
and a lower birthweight compared to the control group
(Table 1). Small for gestational age newborns (below 10th
percentile) were delivered by 9 of 116 women in the nor-
motensive group(8%), compared with 3 of 17 women in
the hypertensive group (18%).
Zymographic characterization of amniotic fluid MMP in 
hypertensive and normotensive pregnancies
The results are presented in Figure 1. Zymography of
amniotic fluid obtained from women with normotensive
pregnancies (n = 20) showed the presence of both 92 kDa
Pro-MMP-9 (479 ± 79.3 optical density/background) and
72 kDa Pro-MMP-2. A different MMP profile was
observed in the hypertensive group (n = 17). In this
group, ProMMP-9 was not demonstrated, while Pro-
MMP-2 was significantly higher (2556 ± 228 versus 5686
± 413 optical density/background, respectively; P <
0.001). In addition, a clear band of active MMP-2 (689 ±
101 optical density/background) and a fourth band (53
kDa), were observed in amniotic fluid collected from
women in the hypertensive group. This forth band (507 ±
105 optical density/background) could possibly represent
MMP-3 (Stromelisyn-1).
Amniotic fluid MMP-2 levels in hypertensive and 
normotensive pregnacies
The hypertensive group included all 17 women who
developed hypertensive disorder during pregnancy. For
the control group we chose 47 random samples from the
116 amniotic fluid samples obtained from normotensive
women. Clinical characteristics and pregnancy outcome
Table 1: Clinical characteristics and pregnancy outcome in the hypertensive and normotensive groups.
Hypertensive (n = 17)
Mean ± SD
Normotensive (n = 116)
Mean ± SD
P
Maternal age 36.53 ± 4.64 34.04 ± 5.11 0.06
Gest. Age at AC 18.88 ± 3.04 19.38 ± 3.12 0.53
Gest. Age at delivery 36.59 ± 2.79 39.54 ± 1.23 <0.01
Method of delivery
Vaginal delivery 10 (58.8%) 82 (70.7%)
Cesarean section 7 (41.2%) 34 (29.3%) 0.40
Fetal gender
Male 7 (41.2%) 63 (54.3%)
Female 10 (58.8%) 53 (45.7%) 0.44
Birthweight 2862 ± 812 3389 ± 436 < 0.01
Apgar score
1 minute 9.25 9.24 0.96
5 minute 9.94 9.97 0.43
Cord pH 7.34 7.34 0.97
AC: amniocentesis.Reproductive Biology and Endocrinology 2009, 7:85 http://www.rbej.com/content/7/1/85
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of this normotensive subgroup did not differ significantly
from the entire normotensive group.
Mean amniotic fluid MMP-2 levels in the hypertensive
group and the control group are presented in figure 2A.
Mean amniotic fluid MMP-2 levels were significantly
higher in women who developed a hypertensive disorder
in pregnancy compared with normotensive pregnancies
(22.3 ± 1.3 ng/ml versus 17.2 ± 0.6 ng/ml, respectively; P
< 0.0004). We further subdivided the hypertensive group
into GH, PET, and sPET. The results are presented in figure
2B. In amniotic fluid of women who eventually devel-
oped PET or sPET, MMP-2 levels were significantly higher
compared to women with normotensive pregnancies
(22.2 ± 1.2 ng/ml and 24.8 ± 1.3 versus 17.2 ± 0.6 ng/ml,
respectively; P < 0.05). Amniotic fluid MMP-2 levels were,
however, not significantly higher in the GH group com-
pared to the control group (figure 2).
Amniotic fluid TIMP-2 levels in hypertensive and 
normotensive pregnancies
The results, presented in Figure 3, showed that TIMP-2
was detected in amniotic fluid of both groups of women
(20 normotensive and 17 hypertensive). The level of
TIMP-2, however, was significantly higher in women who
developed a hypertensive disorder, compared with nor-
motensive women (2277 ± 135 versus 1043 ± 92 optical
density, respectively; P < 0.01).
Conclusion
Preeclampsia, a pregnancy-specific disorder, contributes
substantially to perinatal morbidity and mortality of both
mother and newborn [1].
This study was designed to test second trimester amniotic
fluid MMP levels in women who develop preeclampsia,
prior to clinical presentation of the disease. Our decision
to study MMP-2 levels in amniotic fluid stemmed from
the fact that the amniotic compartment contains MMP-2
which is most reliably fetal in origin, whereas maternal
serum MMP-2 could be of placental origin or influenced
by non-pregnancy related causes, some yet to be deter-
mined
MMP profile in second trimester amniotic fluid of women  with normotensive pregnancies and women who developed a  hypertensive disorder in pregnancy Figure 1
MMP profile in second trimester amniotic fluid of 
women with normotensive pregnancies and women 
who developed a hypertensive disorder in pregnancy. 
Representative zymography gels. A  Secretion of Pro-MMP-9 
and Pro-MMP-2 obtained from second-trimester amniotic 
fluid of women with normotensive pregnancies. B  Secretion 
of Pro-MMP-9, Pro-MMP-2, Active-MMP-2 and a fourth band 
(53 kDa) obtained from second-trimester amniotic fluid of 
women who developed a hypertensive disorder in preg-
nancy. C  Bar graph representing mean ± SEM of MMP secre-
tion, expressed as OD  background, from 37 amniotic fluid 
samples. Black bars represent normotensive pregnancies (n = 
20). White bars represent hypertensive pregnancies (n = 17). 
T-test, *P < 0.001.
Quantitative MMP-2 secretion in second trimester amniotic  fluid of women with normotensive pregnancies and women  who developed a hypertensive disorder in pregnancy Figure 2
Quantitative MMP-2 secretion in second trimester 
amniotic fluid of women with normotensive pregnan-
cies and women who developed a hypertensive disor-
der in pregnancy. MMP-2 secretion expressed as ng/ml 
MMP-2. A  MMP-2 secretion, as detected by ELISA kit 
(detected both pro and active forms) of amniotic fluid sam-
ples from women with normotensive pregnancies (n = 47) 
and women who developed a hypertensive disorder in preg-
nancy (n = 17). T-test, *P < 0.0004. B  Bar graph represent-
ing mean ± SEM quantitative MMP-2 secretion level divided 
into subgroups. T-test, *P < 0.05.Reproductive Biology and Endocrinology 2009, 7:85 http://www.rbej.com/content/7/1/85
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We showed significantly higher levels of MMP-2 in amni-
otic fluid of women who developed a hypertensive disor-
der compared to normotensive women. These findings
were consistent in both the zymographic presentation and
the Elisa test.
Higher levels of MMP-2 were found in the plasma of non-
pregnant patients with hypertension [16]. Several other
studies have found increased plasma MMP-2 levels in
women with preeclampsia [8,15]. Myers at al [15] meas-
ured plasma levels of MMP-2, MMP-9 and TIMP-1,2 at
three different points of gestation (22 weeks, 26 weeks, at
delivery). Women who eventually developed preeclamp-
sia showed increased levels of MMP-2 at 22 weeks but not
at 26 weeks. This study supports our results of elevated
amniotic fluid MMP-2 during the second trimester, prior
to clinical presentation of preeclampsia.
Others found higher total VEGF (vascular endothelial
growth factor), MMP-2, and endothelin-1 concentrations
in umbilical vein endothelial cells of women with preec-
lampsia and showed significant positive correlations
between them [17].
We found increased levels of TIMP-2 in amniotic fluid of
women who eventually developed a hypertensive disor-
der compared with normotensive women. These results
contradict the findings of Myers et al, in which TIMP-2
levels in plasma of women who developed preeclampsia
were not quantifiable. This can be explained by the differ-
ent origin of the tested samples. The mammalian tissue
inhibitor of metalloproteinase (TIMP) family consists of
four proteins (TIMP-1, 2, 3, and 4), and regulates the
activity of MMPs that are capable of degrading extracellu-
lar matrix. It has been hypothesized that, together with
MMP-2 and MT1-MMP (localized to the cell surface mem-
brane), TIMP-2 is vital for initiating angiogenesis [18].
Since early placentation involves trophoblast invasion
into blood vessels and angiogenesis, we might suggest a
role for TIMP-2 in abnormal placentation and angiogen-
esis. Merchant et al [6] found a significantly enhanced
release of MMP-2, TIMP-1, and TIMP-2 from umbilical
vein endothelial cells of preeclamptic women compared
to normotensive women. These findings may provide an
explanation as to the origin of the increased amniotic
fluid MMP-2 and TIMP-2 we found in our study. Higher
TIMP-1 and TIMP-2 levels were also found in the plasma
of women with GH compared with normotensive women
[19].
When further subdivided into groups of GH, PET and
sPET, we found a significant difference in MMP-2 amni-
otic fluid levels between normotensive women and
women who developed PET or sPET. No significant differ-
ence, however, was found between normotensive women
and women with gestational hypertension. Preeclampsia
is a systemic disease characterized not only by hyperten-
sion but also by increased vascular resistance, diffuse
endothelial dysfunction, proteinuria, and coagulopathy.
In the absence of severe disease manifestations, discrimi-
nation between PET and GH may be difficult. This distinc-
tion is often made solely on the basis of urine protein
determination, frequently by dipstick protein measure-
ment, which is recognized to be an imperfect surrogate for
24-hour measurements. Preeclampsia and gestational
hypertension may represent different manifestations of
one disease process and some consider gestational hyper-
tension to be a precursor to preeclampsia [20]. The theory
that hypertension in pregnancy may represent a spectrum
of manifestations, ranging from mild (GH) to severe
symptoms (PET, sPET), may explain our results showing
progressive increase in MMP-2 levels between the GH
group and PET, sPET groups.
Whether this could contribute to the increased amniotic
fluid MMP-2 level in women with chronic hypertention
and superimposed PET in unclear. In our study, all
women with chronic hypertension developed superim-
posed PET. Therefore, we were not able to measure amni-
otic fluid levels of women with chronic hypertension
without sPET.
TIMP-2 expression in second trimester amniotic fluid of  women with normotensive pregnancies and women who  developed a hypertensive disorder in pregnancy Figure 3
TIMP-2 expression in second trimester amniotic fluid 
of women with normotensive pregnancies and 
women who developed a hypertensive disorder in 
pregnancy. Representative Western blot. A  Expression of 
TIMP-2 in second-trimester amniotic fluid obtained from 
women with normotensive pregnancies. B  Expression of 
TIMP-2 in second-trimester amniotic fluid obtained from 
women who developed a hypertensive disorder in preg-
nancy. C  Bar graph representing mean ± SEM of TIMP-2 
expression from 37 amniotic fluid samples. Black bar repre-
sents normotensive pregnancies (n = 20). White bar repre-
sents hypertensive pregnancies (n = 17). T-test, *P < 0.001.Reproductive Biology and Endocrinology 2009, 7:85 http://www.rbej.com/content/7/1/85
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Our study group consisted of women undergoing genetic
second trimester amniocentesis, mostly due to maternal
age (mean age 34 yrs). This fact may explain the relatively
high prevalence of hypertensive disorders (12% in our
study, compared with 5% in the literature), as well as the
relatively high percentage of chronic hypertension with
superimposed preeclampsia (4.8%). We acknowledge
that this is a high-risk population and is not comparable
to the general population. We were not able to study
MMP-2 levels in women with chronic hypertension with-
out superimposed preeclampsia. This would be an inter-
esting subgroup of women to include in further studies.
Although statistical significance has been achieved, one of
the limitations of our study is the small number of hyper-
tensive women. The subdivision into subgroups (GH,
PET, sPET) was further limited by smaller numbers. This
is a preliminary study which should be expanded in order
to validate the results.
Another limitation of the study pertains to the invasive-
ness of the amniocentesis procedure. The invasive nature
of the procedure precludes the use of amniotic fluid MMP-
2 levels as a screening test for preeclampsia, but rather as
a means of gaining further insight into the pathophysiol-
ogy of the disease.
In conclusion, higher levels of MMP-2 and TIMP-2 are
found in the amniotic fluid of women prior to presenta-
tion of preeclampsia. The possibility that these proteins
may have a role in the development of preeclampsia
needs a further study.
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